Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
Source: SeekingAlpha
2025-07-21 17:20:30 ET
Investment Overview
I have covered Evolus ( EOLS ) twice before in notes for Seeking Alpha, the first time in March 2024 , issuing a "Buy" recommendation, and re-iterating that rating in a more recent note, in January this year. Shares are in fact down 34% since my first note, and down 2% since my January note....
Read the full article on Seeking Alpha
For further details see:
Evolus - A Slightly Risky Buy Ahead Of Q2 Earnings
Evolus Inc.
NASDAQ: EOLS
EOLS Trading
-6.91% G/L:
$4.85 Last:
301,893 Volume:
$4.96 Open:
EOLS Latest News
EOLS Stock Data
$288,448,039
43,258,131
1.1%
49
N/A
Pharmaceuticals
Healthcare
US
Newport Beach
